ATTENTION deficit hyperactivity
disorder (ADHD) may be the
subject of overprescription and
overdiagnosis with the implication
that disorders of children in
particular are being “medicalised”,
according to an editorial in the
MJA.
There are risks for children that
the use of stimulant medication is a
“simplistic attempt to find solutions
to more complex problems
underlying behavioural and
emotional difficulties, and risks in
adolescents and adults prescribed
or exposed to stimulants, including
poisonings,” the article states.
The author suggests that
prescription monitoring programs
may have a role to play, although
this has not generally been
successful in Australia as yet.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Mar 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Mar 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.